T-DM1, Lapatinib, Nab-paclitaxel in HER2+ Breast Cancer T-DM1, Lapatinib, Nab-paclitaxel in HER2+ Breast Cancer

Should dual HER2 blockade plus nab-paclitaxel be considered for neoadjuvant treatment of HER2+ breast cancer?Breast Cancer Research
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news